[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[2]
|
Perou, C.M., Sorlie, T., Eisen, M.B., et al. (2000) Molecular Por-traits of Human Breast Tumours. Nature, 406, 747-752. https://doi.org/10.1038/35021093
|
[3]
|
Johnson, K.S., Conant, E.F. and Soo, M.S. (2021) Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging, 3, 12-24. https://doi.org/10.1093/jbi/wbaa110
|
[4]
|
Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122.
|
[5]
|
Al-thoubaity, F.K. (2020) Molecular Classification of Breast Cancer: A Retrospective Cohort Study. Annals of Medicine and Surgery, 49, 44-48. https://doi.org/10.1016/j.amsu.2019.11.021
|
[6]
|
金振硕, 王海燕. 通过JAK通路促进乳腺癌的免疫治疗[J]. 中国免疫学杂志, 2019, 35(23): 2942-2945.
|
[7]
|
Ravdin, P.M. and Chamness, G.C. (1995) The c-erbB-2 Proto-Oncogene as a Prognostic and Predictive Marker in Breast Cancer: A Para-digm for the Development of Other Macromolecular Markers—A Review. Gene, 159, 19-27.
https://doi.org/10.1016/0378-1119(94)00866-Q
|
[8]
|
Bredin, P., Walshe, J.M. and Denduluri, N. (2020) Systemic Therapy for Metastatic HER2-Positive Breast Cancer. Seminars in Oncology, 47, 259-269. https://doi.org/10.1053/j.seminoncol.2020.07.008
|
[9]
|
Zhang, L., Li, Z.J., Zhang, J., et al. (2020) De Novo Meta-static Breast Cancer: Subgroup Analysis of Molecular Subtypes and Prognosis. Oncology Letters, 19, 2884-2894. https://doi.org/10.3892/ol.2020.11359
|
[10]
|
Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Trans-forming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. https://doi.org/10.1038/sj.onc.1210477
|
[11]
|
Singh, H., Walker, A.J., Amiri-Kordestani, L., et al. (2018) US Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. Clinical Cancer Research, 24, 3486-3491.
https://doi.org/10.1158/1078-0432.CCR-17-3628
|
[12]
|
Howie, L.J., Scher, N.S., Amiri-Kordestani, L., et al. (2019) FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. Clinical Cancer Research, 25, 2949-2955.
https://doi.org/10.1158/1078-0432.CCR-18-3003
|
[13]
|
Saura, C., Oliveira, M., Feng, Y.H., et al. (2020) Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with ≥2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 38, 3138-3149. https://doi.org/10.1200/JCO.20.00147
|
[14]
|
Chumsri, S., Li, Z., Serie, D.J., et al. (2019) Incidence of Late Relapses in Patients with HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology, 37, 3425-3435. https://doi.org/10.1200/JCO.19.00443
|
[15]
|
Drago, J.Z., Modi, S. and Chandarlapaty, S. (2021) Unlocking the Po-tential of Antibody-Drug Conjugates for Cancer Therapy. Nature Reviews Clinical Oncology, 18, 327-344. https://doi.org/10.1038/s41571-021-00470-8
|
[16]
|
Nagayama, A., Ellisen, L.W., Chabner, B., et al. (2017) Anti-body-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted On-cology, 12, 719-739.
https://doi.org/10.1007/s11523-017-0535-0
|
[17]
|
Jain, N., Smith, S.W., Ghone, S., et al. (2015) Current ADC Linker Chemistry. Pharmaceutical Research, 32, 3526-3540. https://doi.org/10.1007/s11095-015-1657-7
|
[18]
|
Beck, A., Goetsch, L., Dumontet, C., et al. (2017) Strategies and Challenges for the Next Generation of Antibody Drug Conjugates. Nature Reviews Drug Discovery, 16, 315-337. https://doi.org/10.1038/nrd.2016.268
|
[19]
|
Norsworthy, K.J., Ko, C.W., Lee, J.E., et al. (2018) FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. Oncologist, 23, 1103-1108.
https://doi.org/10.1634/theoncologist.2017-0604
|
[20]
|
Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/NEJMoa2203690
|
[21]
|
Hafeez, U., Parakh, S., Gan, H.K., et al. (2020) Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25, Article No. 33. https://doi.org/10.3390/molecules25204764
|
[22]
|
Burris, H.A., Rugo, H.S., Vukelja, S.J., et al. (2011) Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Re-ceptor 2 (HER2)-Positive Breast Cancer after Prior HER2-Directed Therapy. Journal of Clinical Oncology, 29, 398-405. https://doi.org/10.1200/JCO.2010.29.5865
|
[23]
|
Krop, I.E., Kim, S.B., Martin, A.G., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncolo-gy, 18, 743-754.
https://doi.org/10.1016/S1470-2045(17)30313-3
|
[24]
|
Cardoso, F., Paluch-Shimon, S., Senkus, E., et al. (2020) 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Annals of Oncology, 31, 1623-1649. https://doi.org/10.1016/j.annonc.2020.09.010
|
[25]
|
Von Minckwitz, G., Huang, C.S., Mano, M.S., et al. (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medi-cine, 380, 617-628. https://doi.org/10.1056/NEJMoa1814017
|
[26]
|
Modi, S., Saura, C., Yamashita, T., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 382, 610-621. https://doi.org/10.1056/NEJMoa1914510
|
[27]
|
Hurvitz, S.A., Hegg, R., Chung, W.P., et al. (2023) Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Up-dated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial. The Lancet, 401, 105-117. https://doi.org/10.1016/S0140-6736(22)02420-5
|
[28]
|
Diéras, V., Deluche, E., Lusque, A., et al. (2022) Trastuzumab Deruxtecan (T-DXd) for Advanced Breast Cancer Patients (ABC), Regardless HER2 Status: A Phase II Study with Biomarkers Analysis (DAISY). Cancer Research, 82, PD8-02. https://doi.org/10.1158/1538-7445.SABCS21-PD8-02
|
[29]
|
Powell, C.A., Modi, S., Iwata, H., et al. (2022) Pooled Analysis of Drug-Related Interstitial Lung Disease and/or Pneumonitis in Nine Trastuzumab Deruxtecan Monotherapy Studies. ESMO Open, 7, Article ID: 100554.
https://doi.org/10.1016/j.esmoop.2022.100554
|
[30]
|
Banerji, U., van Herpen, C.M.L., Saura, C., et al. (2019) Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. The Lancet Oncology, 20, 1124-1135. https://doi.org/10.1016/S1470-2045(19)30328-6
|
[31]
|
Manich, C.S., O’Shaughnessy, J., Aftimos, P.G., et al. (2021) Primary Outcome of the Phase III SYD985.002/TULIP Trial Comparing Vic-Trastuzumab Duocarmazine to Physician’s Choice Treatment in Patients with Pre-Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer. Annals of Oncology, 32, S1288.
https://doi.org/10.1016/j.annonc.2021.08.2088
|
[32]
|
Li, H.W., Yu, C., Jiang, J., et al. (2016) An Anti-HER2 Anti-body Conjugated with Monomethyl Auristatin E Is Highly Effective in HER2-Positive Human Gastric Cancer. Cancer Biology & Therapy, 17, 346-354.
https://doi.org/10.1080/15384047.2016.1139248
|
[33]
|
Wang, J.Y., Liu, Y.J., Zhang, Q.Y., et al. (2021) RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive and HER2-Low Expressing Advanced or Metastatic Breast Cancer: A Pooled Analysis of Two Studies. Journal of Clinical Oncology, 39, Article No. 1022. https://doi.org/10.1200/JCO.2021.39.15_suppl.1022
|
[34]
|
Zhang, J., Ji, D.M., Shen, W.A., et al. (2022) Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 28, 4212-4221.
https://doi.org/10.1158/1078-0432.CCR-22-0456
|
[35]
|
Cortés, J., Kim, S.B., Chung, W.P., et al. (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 386, 1143-1154. https://doi.org/10.1056/NEJMoa2115022
|
[36]
|
Bardia, A., Hurvitz, S.A., Rugo, H.S., et al. (2021) A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer. Future Oncology, 17, 3911-3924.
https://doi.org/10.2217/fon-2021-0868
|
[37]
|
Kolberg, H.C., Andre, F., Hamilton, E., et al. (2022) Trastuzumab Deruxtecan (T-DXd) Combinations in Patients with HER2-Positive Advanced or Metastatic Breast Cancer: A Phase 1b/2, Open-Label, Multicenter, Dose-Finding and Dose-Expansion Study (DESTINY-Breast07). Oncology Research and Treatment, 45, 32-32.
|